title: Combined oral contraceptives in the treatment of polycystic ovary syndrome.
abstract: Combined oral contraceptives (COC) are the most often used treatment modality for polycystic ovary syndrome (PCOS). Undisputedly, COC suppress androgen production, thus ameliorating skin androgenic symptoms and improving menstrual dysfunction. On the other hand, there are still many unresolved issues concerning their metabolic effects. COC could decrease insulin sensitivity and deteriorate glucose tolerance, although the negative influence on insulin sensitivity is dependent on other factors (especially obesity) and this need not be expressed in non-obese patients. It is probable that the impairment of glucose tolerance is reversible, as the incidence of diabetes is not increased in past COC users. The effects of COC on the lipid spectrum are dependent on the type of gestagen, but lipid levels usually remain within the reference limits. Combination therapy of COC with weight reduction or insulin sensitizers could further suppress androgen levels and improve metabolic parameters. The establishment of COC after laparoscopic ovarian drilling may further decrease androgen levels. The combination of COC and GnRH analogues is not superior to COC therapy alone. Prospective data about the influence of COC on the risk of diabetes mellitus, coronary artery disease and endometrial cancer in PCOS women are lacking.
authors.affiliation: Department of Clinical Endocrinology, Institute of Endocrinology, Narodni 8, Prague 1, 116 94, Czech Republic.
authors.forename: J
authors.initials: J
authors.lastname: Vrbíková
authors.forename: D
authors.initials: D
authors.lastname: Cibula
mesh_terms: D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*
chemical_list: D003278:Contraceptives, Oral, Hormonal